SAMA Schultze Special Purpose Acquisition

Clever Leaves and Astrasana Partner to Establish International Supply Agreement For Medical Cannabis Extracts in Czech Republic and Switzerland

Clever Leaves and Astrasana Partner to Establish International Supply Agreement For Medical Cannabis Extracts in Czech Republic and Switzerland

TOCANCIPÁ, Colombia, May 30, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves”), a global medicinal cannabis company, announced today the arrival of the company’s first shipment of medical cannabis extracts from Colombia to Switzerland-based partner, Astrasana Holding AG (“Astrasana”). This marks the first commercial shipment for Clever Leaves to Switzerland, where Astrasana is an established medical cannabis distributor.

Additionally, Clever Leaves and Astrasana are preparing for the first shipment of medical cannabis extracts to the Czech Republic, where Astrasana has pharmaceutical operations and manages its own pharmacy specialising in the sale of medical cannabis.

The supply agreement between Clever Leaves and Astrasana will allow Clever Leaves to expand into new European markets and further solidify its position as a global provider of medical cannabis. Switzerland and the Czech Republic have both seen recent legislative changes in favor of medical cannabis and are at the forefront of the emerging European cannabis industry.

“The Supply Agreement guarantees Astrasana a reliable and consistent supply of medical cannabis extracts at competitive prices, providing planning certainty and allowing for seamless operations,” says CEO of Astrasana Holding, Yves Antoniazzi. “This partnership with Clever Leaves not only ensures a steady supply of premium medical cannabis products for Astrasana's customers, but also intensifies the existing collaboration between the two companies, paving the way for future growth opportunities.”

Clever Leaves, a publicly traded company with a well-regarded reputation in the cannabis industry, has been operating since 2016 and is known for its expertise in producing high-quality medical cannabis extracts. The company's commitment to upholding the highest standards in the industry aligns perfectly with Astrasana's values and mission to provide safe and effective medical cannabis products to patients worldwide.

"Clever Leaves' first commercial shipment of medical cannabis extracts to Astrasana in Switzerland marks a significant step towards our goal of expanding patient access to high-quality medical cannabis across Europe and beyond. Through our strategic partnership with Astrasana, we look forward to aligning our capabilities and further penetrating new countries in Europe such as Switzerland and Czech Republic. As a company, we remain focused on driving innovation in the industry and creating safe, pharmaceutical-grade products for patients in need,” said Co-Founder and CEO of Clever Leaves, Andres Fajardo.

  

With Clever Leaves' global reach and expertise in the cannabis industry, Astrasana is poised to further strengthen its position as a leading provider and distributor of medical cannabis in the Czech Republic and Switzerland.

About Astrasana

Astrasana is a pioneering company in the field of medical cannabis, with manufacturing and retail locations in the Czech Republic and Switzerland. With comprehensive pharmaceutical licenses and a strong focus on quality, sustainability, innovation, and customer satisfaction, Astrasana is dedicated to providing safe and effective medical cannabis products to patients. Astrasana's board of directors consists of doctors and pharmacists which allow the company to have a competitive advantage.

About Clever Leaves Holdings Inc.

Clever Leaves is a global medical cannabis company. Its operations in Colombia produce EU GMP cannabinoid active pharmaceutical ingredients (API) and finished products ​in flower and extract form to a growing base of B2B customers around the globe. Clever Leaves aims to disrupt the traditional cannabis production industry by leveraging environmentally sustainable, ESG-friendly, industrial-scale and low-cost production methods, with the world’s most stringent pharmaceutical quality certifications. For more information, please visit /en/home/ and follow Clever Leaves on Twitter and LinkedIn. 

Clever Leaves Press Contacts:

Maria Petsanas

KCSA Strategic Communications

|

Clever Leaves Investor Inquiries:

Cody Slach and Jackie Keshner

Gateway Group, Inc.

|

Clever Leaves Commercial Contact:

Andrew Miller

Head of Global Business Development



 



EN
30/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Schultze Special Purpose Acquisition

 PRESS RELEASE

Clever Leaves Announces Voluntary Delisting and SEC Deregistration

Clever Leaves Announces Voluntary Delisting and SEC Deregistration TOCANCIPÁ, Colombia, April 26, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, today announced that its Board of Directors (the “Board”) determined to voluntarily delist its common shares, without par value (the “common shares”) and warrants, each exercisable for 1/30th common share at an exercise price of $11.50 (the “Warrants” and together with the common shares, the “Securities”) from The Nasdaq Stock Market LLC (“Nasdaq”...

 PRESS RELEASE

Clever Leaves Reports Fourth Quarter and Full Year 2023 Results

Clever Leaves Reports Fourth Quarter and Full Year 2023 Results - 2023 Revenue Increased 6% Year-Over-Year, with a 39% Increase in Full-Year Cannabinoid Revenue - - Drove Year-over-Year General and Administrative Expense Reductions of 26% in Q4 2023 and 24% for the Full Year - - Completed Sale of Non-Cannabinoid Herbal Brands Business on March 21, 2024 for $8.02 Million, Including $7.02 Million in Cash Paid at Closing - TOCANCIPÁ, Colombia, April 01, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabi...

 PRESS RELEASE

Clever Leaves and Paradise Seeds to Develop and Register Genetic Asset...

Clever Leaves and Paradise Seeds to Develop and Register Genetic Assets in Colombia TOCANCIPÁ, Colombia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, announced today that through its partnership with award-winning Dutch seed bank, Paradise Seeds (“Paradise”), to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third parties for...

 PRESS RELEASE

Clever Leaves Granted Australian GMP Certification for Cannabis Produc...

Clever Leaves Granted Australian GMP Certification for Cannabis Products by the Therapeutic Goods Administration (TGA) Multinational operator has been granted Australian GMP certification by the TGA for the manufacturing of cannabis products. Clever Leaves is the first and only medicinal cannabis company globally that has GMP certifications from the European Union, Colombia, Brazil and Australia. TOCANCIPÁ, Colombia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW), a global medicinal cannabis company, announced today that it has been granted Australia...

 PRESS RELEASE

Clever Leaves Reports Third Quarter 2023 Results

Clever Leaves Reports Third Quarter 2023 Results - Q3 Revenue Increased 33% Year-Over-Year, Propelled by 135% Year-Over-Year Growth in Cannabinoid Revenue, Along with 6% Year-Over-Year Growth in Non-Cannabinoid Revenue - - Q3 Adjusted EBITDA Improved Year-Over-Year to $(2.6) Million Compared to $(3.7) Million, Reflecting Revenue Growth and Continued Aggressive Expense Reductions - - Cash Balance at October 31, 2023 was $6.2 Million, with $1.9 Million in Subsequent Capital Received from the November Sale of the Company’s Remaining Stake in Cansativa - - Updated Full Ye...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch